Five years later, Europe reinstates aprotinin
This article was originally published in Scrip
Executive Summary
The European Commission has approved recommendations to reinstate aprotinin (Trasylol; Nordic Group) marketing authorizations in the region – products containing the drug were suspended by the regulator in 2008.